Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (106)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Semiglazov, V. E.
Right arrow Articles by Chepic, O. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semiglazov, V. E.
Right arrow Articles by Chepic, O. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 5:591-595, 1994
© 1994 European Society for Medical Oncology

research-article

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer

V. E. Semiglazov, E. E. Topuzov, J. L. Bavli, V. M. Moiseyenko, O. A. Ivanova, I. K. Seleznev, A. A. Orlov, N. Y. Barash, O. M. Golubeva and O. F. Chepic

N. N. Petrov Research Institute of Oncology of the Russian Academy of Medical Sciences St. Petersburg, Russia

Correspondence to: V. F. Semiglazov, M.D., N. N. Petrov Research Institute of Oncology of the Russian Academy of Medical Sciences, Leningradskay Street 68, Pesochny-2, St. Petersburg, Russia

BACKGROUND:: A phase III randomized trial was activated to evaluate the efficacy of preoperative combined chemotherapy and radiotherapy as compared to preoperative radiation therapy alone, in patients with breast cancer presenting with a clinical stage of IIb-IIIa (TNM classification).

PATIENTS AND METHODS:: From 1985 to 1990, 271 patients, aged 27–55 years, with stage IIb-IIIa breast cancer were randomized to receive either one or two courses of thio-tepa 20 mg (i.m. injection) on the days 1, 3, 5, 7, 9, 11 (total dose per course 120 mg), methotrexate 40 mg/m2, i.v. on days 1 and 8, and 5-fluorouracil 500 mg/m2, i.v. on days 1 and 8 (IMF regimen) plus radiotherapy (Group I, 137 patients), or preoperative radiation therapy only (Group n, 134 patients). After the preoperative treatment all patients underwent mastectomy and complete axillary clearance, and then received 4–6 courses of TMF. The trial was conducted in a single institution (N. N. Petrov Research Institute of Oncology, St. Petersburg).

RESULTS:: Histopathological assessment of the mastectomy specimens showed complete regression of the tumour in 29.1% of the patients in group I and in 19.4% of the patients e.c. in group n. The estimated 5-year overall survival percentages were 86.1% for group I, and 78.3% for group II (P > 0.05). 5-year disease-free survival percentages were 81.0% and 71.6%, respectively (p < 0.05).

CONCLUSIONS:: Despite the low number of the patients included in the trial, we were able to detect a significant improvement in treatment results with a combination of chemotherapy and radiation therapy given prior to mastectomy over those of local therapy alone with radiation therapy followed by mastectomy, for average and high-risk patients with operable breast cancer.

neoadjuvant chemotherapy, radiotherapy, breast cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
J. R. Gralow, H. J. Burstein, W. Wood, G. N. Hortobagyi, L. Gianni, G. von Minckwitz, A. U. Buzdar, I. E. Smith, W. F. Symmans, B. Singh, et al.
Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
J. Clin. Oncol., February 10, 2008; 26(5): 814 - 819.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Guarneri, K. Broglio, S.-W. Kau, M. Cristofanilli, A. U. Buzdar, V. Valero, T. Buchholz, F. Meric, L. Middleton, G. N. Hortobagyi, et al.
Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors
J. Clin. Oncol., March 1, 2006; 24(7): 1037 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schmid, J. Krocker, C. Jehn, K. Michniewicz, S. Lehenbauer-Dehm, H. Eggemann, V. Heilmann, S. Kummel, C. O. Schulz, A. Dieing, et al.
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial
Ann. Onc., October 1, 2005; 16(10): 1624 - 1631.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Popat and I. E. Smith
Re: Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
J Natl Cancer Inst, June 1, 2005; 97(11): 858 - 858.
[Full Text] [PDF]

Home page
 JCOHome page
T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al.
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Mauri, N. Pavlidis, and J. P. A. Ioannidis
Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
J Natl Cancer Inst, February 2, 2005; 97(3): 188 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. J. Cleator, A. Makris, S. E. Ashley, R. Lal, and T. J. Powles
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival
Ann. Onc., February 1, 2005; 16(2): 267 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, P. Veronesi, R. D. Gelber, G. Curigliano, R. Torrisi, A. Luini, et al.
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment
Clin. Cancer Res., October 1, 2004; 10(19): 6622 - 6628.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. S. Mano and A. Awada
Primary chemotherapy for breast cancer: the evidence and the future
Ann. Onc., August 1, 2004; 15(8): 1161 - 1171.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
I. E. Smith, R. P. A'Hern, G. A. Coombes, A. Howell, S. R. Ebbs, T. F. Hickish, M. E. R. O'Brien, J. L. Mansi, C. B. Wilson, A. C. Robinson, et al.
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial
Ann. Onc., May 1, 2004; 15(5): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. H. Giordano
Update on Locally Advanced Breast Cancer
Oncologist, December 1, 2003; 8(6): 521 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes
Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study
Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. C. Wolff and N. E. Davidson
Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease
Oncologist, June 1, 2002; 7(3): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. C. Smith, S. D. Heys, A. W. Hutcheon, I. D. Miller, S. Payne, F. J. Gilbert, A. K. Ah-See, O. Eremin, L. G. Walker, T. K. Sarkar, et al.
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
J. Clin. Oncol., March 15, 2002; 20(6): 1456 - 1466.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Rouzier, J.-M. Extra, J. Klijanienko, M.-C. Falcou, B. Asselain, A. Vincent-Salomon, P. Vielh, and E. Bourstyn
Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes
J. Clin. Oncol., March 1, 2002; 20(5): 1304 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Mauriac, M. Debled, M. Durand, A. Floquet, V. Boulanger, C. Dagada, N. Trufflandier, and G. MacGrogan
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women
Ann. Onc., February 20, 2002; 13(2): 293 - 298.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
G. N Hortobagyi
Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview
J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 72 - 79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau
Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902
J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237.
[Abstract] [Full Text]

Home page
 JCOHome page
R. Rouzier, J.-M. Extra, M. Carton, M.-C. Falcou, A. Vincent-Salomon, A. Fourquet, P. Pouillart, and E. Bourstyn
Primary Chemotherapy for Operable Breast Cancer: Incidence and Prognostic Significance of Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery
J. Clin. Oncol., September 15, 2001; 19(18): 3828 - 3835.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Aapro
Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001
Oncologist, August 1, 2001; 6(4): 376 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. C. Wolff and N. E. Davidson
Primary Systemic Therapy in Operable Breast Cancer
J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. D. Miller, W. McCaskill-Stevens, J. Sisk, D. M. Loesch, F. Monaco, R. Seshadri, and G. W. Sledge Jr
Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group
J. Clin. Oncol., October 1, 1999; 17(10): 3033 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Valero, A. U. Buzdar, and G. N. Hortobagyi
Locally Advanced Breast Cancer
Oncologist, February 1, 1996; 1(1): 8 - 17.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.